item management s discussion and analysis of financial condition and results of operations this discussion contains forward looking statements and such statements are subject to certain risks and uncertainties which could cause actual results to differ materially from those projected 
factors that could cause or contribute to such differences include  but are not limited to  the factors discussed below and in business and additional business risks  as well as those discussed elsewhere in this annual report on form k 
overview since its inception  the company has been engaged in the discovery and development of novel therapeutics including both small molecule drugs and therapeutic viruses that are based upon the genetics of human disease 
the company has initially chosen to focus its research in the area of cancer 
the company intends to pursue its therapeutic discovery programs independently and in collaboration with pharmaceutical companies  and to collaborate with such companies on the development and commercialization of any products that may result from the company s discovery programs 
the company has entered into collaborative agreements with bayer in the area of ras oncogenes and eli lilly on the function of the brca gene in breast cancer 
the company has also entered into two separate collaborative agreements with warner lambert  one in cell cycle mutations in cancer and a second pertaining to inflammation and autoimmunity 
as of february   the collaboration with bayer in the ras program transitioned from research activities to co development of a clinical candidate 
the company has not been profitable since inception and expects to incur substantial and increasing losses for the foreseeable future  primarily due to the expansion of its research and development programs  including preclinical studies and clinical trials 
the company expects that losses will fluctuate from quarter to quarter and that such fluctuations may be substantial 
as of december   the company s accumulated deficit was approximately million 
the company s business is subject to significant risks  including the risks inherent in its research and development efforts  uncertainties associated with obtaining and enforcing patents  the lengthy and expensive regulatory approval process and competition from other products 
the company does not expect to generate revenues from the sale of proposed products in the foreseeable future 
results of operations years ended december   and revenue revenue from collaborative research and development agreements contract revenue with bayer  eli lilly and warner lambert accounted for approximately of the company s total revenue in and of the company s total revenue in both and contract revenue for the years ended december   and was million  million and million  respectively 
contract revenue recorded from bayer accounted for approximately million or of total contract revenue for  million or of total contract revenue for and million or of total contract revenue for contract revenue recorded from eli lilly accounted for approximately million or of total contract revenue in  million or of total contract revenue in and  or of total contract revenue in contract revenue recorded from warner lambert for the cell cycle program accounted for approximately million or of total contract revenue in  million or of total contract revenue in and million or of total contract revenue in contract revenue recorded from warner lambert for the inflammation program was million or of total contract revenue in in  no funds were received and no revenue was recognized from warner lambert for the inflammation agreement 
the company anticipates that its contract revenue for will be less than due to the conclusion of the research funding phase of the bayer collaboration agreement on january  research and development expenses research and development expenses were million  million and million during the years ended december   and  respectively 
the expense increase of was primarily due to additional costs associated with phase i and phase ii clinical trials of onyx  the lead product in the company s p program 
additionally  expenses increased over the same period in due to higher research expenses in the company s therapeutic virus program 
the expense increase of was due to increased payroll and personnel expenses as the company hired additional research and development staff and increased expenses in connection with the preclinical and clinical development of onyx research under the company s collaboration agreements with bayer  eli lilly and warner lambert is fully funded by the collaborative partners up to specified levels 
the company expects to continue to expand the scope of its research and development programs in future periods  which may result in substantial increases in research and development expenses  including costs associated with clinical development of onyx in the p therapeutic virus program 
these research and development expenses may not be funded by collaborative partners 
general and administrative expenses general and administrative expenses were million  million and million during the years ended december   and  respectively 
general and administrative expenses in were essentially unchanged over the expense increase of over the same period in was primarily due to increased administrative staffing and higher expenses in connection with the company s reporting and other requirements associated with operating as a publicly held company 
net interest income the company had net interest income of million  million and million during the years ended december   and  respectively 
net interest income decreased by in primarily due to interest expense on a line of credit arrangement entered into in december net interest income increased in over the same period in due to a higher average balance of cash  cash equivalents and short term investments resulting from the company s initial public offering of common stock in may the ipo and an equity investment of million from warner lambert in may liquidity and capital resources since inception  the company s cash expenditures have substantially exceeded its revenues and the company has relied primarily on the proceeds from the sale of equity securities and revenue from collaborative research and development agreements to fund its operations 
at december   the company had cash and investments of million compared to million and million at december  and  respectively 
the decrease of million in was primarily due to cash used in operations of million  debt service of million and capital expenditures of million primarily offset by the issuance of  shares of common stock to two institutional investors  raising an additional million in net proceeds 
the decrease of million in was due to cash used in operations of million and capital expenditures of million offset by debt financing of million and a warner lambert equity investment of million 
the increase in cash and investments of million in was due to million of net proceeds from the ipo and million from a warner lambert equity investment offset by cash used in operations of million 
the company s cash used in operations was million in  million in and million in this cash was used primarily to fund increasing levels of research and development and the general and administrative expenses necessary to support increased operations 
capital expenditures amounted to million in  as compared to million in and million in the company expects to make expenditures for capital additions of approximately million in the company records and amortizes over the related vesting periods deferred compensation representing the difference between the exercise price of options granted and the deemed fair value of its common stock at the time of grant 
options generally vest over four years 
deferred compensation of  and  was recorded in and  respectively 
the amortization of deferred compensation was   and  respectively  for the years ended december   and amortization of deferred compensation over the next fiscal year  including compensation recognized to date  will aggregate to  as such options vest 
the company believes that its existing capital resources and interest thereon and anticipated revenues from existing collaborations will be sufficient to fund its current and planned operations into the year there can be no assurance  however  that changes in the company s research and development plans or other changes affecting the company s operating expenses will not result in the expenditure of such resources before such time  and in any event  the company will need to raise substantial additional capital to fund its operations in future periods 
the company intends to seek such additional funding through collaborative arrangements  public and private equity or debt financings  capital lease transactions or other financing sources that may be available 
however  there can be no assurance that additional financing will be available on acceptable terms or at all 
if additional funds are raised by issuing equity securities  substantial dilution to existing stockholders may result 
if adequate funds are not available  the company may be required to delay  reduce the scope of or eliminate one or more of its research or development programs or to obtain funds through collaborative arrangements with others that are on unfavorable terms or that may require the company to relinquish rights to certain of its technologies  product candidates or products that the company would otherwise seek to develop itself 
impact of the year computer programs using two rather than four digits to identify the year in a date field may cause computer systems to malfunction in the year any computer programs that have time related software may determine a date using as the year rather than the year this could result in a system failure or miscalculations causing disruptions of operations  including  among other things  a temporary inability to engage in specific business activities 
the company has appointed a task force comprised of certain members of management to initiate and monitor a year yk program 
the company s plan to resolve the yk issue involves the following three phases assessment  implementation of action plans and testing of systems to ensure compliance 
the company has completed its assessment phase and has determined that the financial and information technology systems of the company are yk compliant 
the company has also identified certain scientific research and development systems applications that need to be upgraded or replaced in order to be yk compliant 
the company intends to upgrade or replace the computer systems  software and instrumentation that it deems critical to its operation by september  there can be no assurance that the company will be able to upgrade any or all of its systems in accordance with its yk program or  once upgraded  that the systems will be yk compliant 
the company is gathering information about the yk compliance status of its significant suppliers and other third parties with which it has relationships 
the company is requesting that its outside suppliers and other third parties notify the company in writing of the status of their yk compliance programs 
to date  the company is not aware of any outside supplier or other third party with a yk issue that would materially impact the company s business operations 
however  there can be no assurance that the company s outside suppliers and other third parties will be successful in their yk compliance efforts 
the company believes that its costs associated with the upgrade and or conversion of existing computer software and hardware relating to the yk issue will be less than  based on modifications to date as well as the amount of scientific research and development equipment that may have to be upgraded 
in the event that the company does not upgrade its systems in a timely manner  the company may encounter problems with the completion of certain scientific research and development experiments 
the company does not currently have a contingency plan in the event that the company s or its significant suppliers systems are not yk compliant 
item a 
quantitative and qualitative disclosures about market risk interest rate risk the company s exposure to market rate risk for changes in interest rates relates primarily to the company s investment portfolio 
the company does not use derivative financial instruments in its investment portfolio 
by policy  the company places its investments with high quality debt security issuers  limits the amount of credit exposure to any one issuer  limits duration by restricting the term  and holds investments to maturity except under rare circumstances 
the company classifies its cash equivalents or short term investments as fixed rate if the rate of return on an instrument remains fixed over its term 
as of december   all of the company s cash equivalents and short term investments are classified as fixed rate 
the table below presents the amounts and related weighted interest rates of the company s cash equivalents and short term investments at december  fair value average maturity in millions interest rate cash equivalents  fixed rate daily short term investments  fixed rate year short term investments  fixed rate years 
